Zentalis Pharmaceuticals, Inc.
ZNTL
$1.77
-$0.04-2.21%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 37.37% | 31.73% | 9.15% | -23.39% | -23.44% |
| Total Depreciation and Amortization | -7.23% | -7.09% | -6.17% | -2.59% | 10.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -93.29% | -82.41% | -79.02% | 32.10% | 45.43% |
| Change in Net Operating Assets | 290.97% | 189.93% | -151.35% | -55.75% | -103.60% |
| Cash from Operations | 16.03% | 16.43% | -29.28% | -26.91% | -25.15% |
| Capital Expenditure | 30.88% | 77.33% | 70.31% | 77.12% | 87.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 847.32% | -150.32% | 72.80% | 60.70% | 74.79% |
| Cash from Investing | 815.21% | -151.53% | 72.75% | 61.06% | 75.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.88% | -99.80% | -8.83% | -9.09% | 27.74% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.96% | -99.89% | -8.93% | -9.09% | 28.39% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -201.80% | -208.57% | -74.57% | 11.32% | 6,060.79% |
